It was reported in early April that US hedge fund Farallon Capital Management was planning to launch a proxy fight at cancer drug maker Exelixis Inc., and had nominated three directors to that company's board. Farallon, which owns more than 7% of the biotech and is its largest active shareholder, had expressed concerns over what it said was Exelixis' undisciplin